<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>00840140710496</udiDi>
    <basicUdiDi>B-00840140710496</basicUdiDi>
    <tradeName>NeuN</tradeName>
    <deviceName>NeuN</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2178MP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:39:11.304Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710489</udiDi>
    <basicUdiDi>B-00840140710489</basicUdiDi>
    <tradeName>NeuN</tradeName>
    <deviceName>NeuN</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2178MT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:39:10.500Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710472</udiDi>
    <basicUdiDi>B-00840140710472</basicUdiDi>
    <tradeName>NeuN</tradeName>
    <deviceName>NeuN</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2178MS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:39:06.501Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710465</udiDi>
    <basicUdiDi>B-00840140710465</basicUdiDi>
    <tradeName>NeuN</tradeName>
    <deviceName>NeuN</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2178ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:39:05.701Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710458</udiDi>
    <basicUdiDi>B-00840140710458</basicUdiDi>
    <tradeName>Napsin-A</tradeName>
    <deviceName>Napsin-A</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2294MP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:39:04.909Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710441</udiDi>
    <basicUdiDi>B-00840140710441</basicUdiDi>
    <tradeName>Napsin-A</tradeName>
    <deviceName>Napsin-A</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2294MT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:39:04.099Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710434</udiDi>
    <basicUdiDi>B-00840140710434</basicUdiDi>
    <tradeName>Napsin-A</tradeName>
    <deviceName>Napsin-A</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2294MS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:39:00.097Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710427</udiDi>
    <basicUdiDi>B-00840140710427</basicUdiDi>
    <tradeName>Napsin-A</tradeName>
    <deviceName>Napsin-A</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2294ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:38:59.496Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710410</udiDi>
    <basicUdiDi>B-00840140710410</basicUdiDi>
    <tradeName>Myosin, SMHC</tradeName>
    <deviceName>Myosin, SMHC</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2229MP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:38:59.069Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710403</udiDi>
    <basicUdiDi>B-00840140710403</basicUdiDi>
    <tradeName>Myosin, SMHC</tradeName>
    <deviceName>Myosin, SMHC</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2229MT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:38:57.717Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710397</udiDi>
    <basicUdiDi>B-00840140710397</basicUdiDi>
    <tradeName>Myosin, SMHC</tradeName>
    <deviceName>Myosin, SMHC</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2229MS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:38:53.767Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710380</udiDi>
    <basicUdiDi>B-00840140710380</basicUdiDi>
    <tradeName>Myosin, SMHC</tradeName>
    <deviceName>Myosin, SMHC</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2229ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:38:53.028Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710373</udiDi>
    <basicUdiDi>B-00840140710373</basicUdiDi>
    <tradeName>CEACAM5</tradeName>
    <deviceName>CEACAM5</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2661RP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:38:52.308Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710366</udiDi>
    <basicUdiDi>B-00840140710366</basicUdiDi>
    <tradeName>CEACAM5</tradeName>
    <deviceName>CEACAM5</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2661RT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:38:51.844Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710335</udiDi>
    <basicUdiDi>B-00840140710335</basicUdiDi>
    <tradeName>Myogenin</tradeName>
    <deviceName>Myogenin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2462MP</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:38:47.290Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710328</udiDi>
    <basicUdiDi>B-00840140710328</basicUdiDi>
    <tradeName>Myogenin</tradeName>
    <deviceName>Myogenin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2462MT</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:38:46.493Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710359</udiDi>
    <basicUdiDi>B-00840140710359</basicUdiDi>
    <tradeName>CEACAM5</tradeName>
    <deviceName>CEACAM5</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2661RS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:38:45.698Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710342</udiDi>
    <basicUdiDi>B-00840140710342</basicUdiDi>
    <tradeName>CEACAM5</tradeName>
    <deviceName>CEACAM5</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2661RL</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:38:44.895Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710311</udiDi>
    <basicUdiDi>B-00840140710311</basicUdiDi>
    <tradeName>Myogenin</tradeName>
    <deviceName>Myogenin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2462MS</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:38:28.033Z</lastUpdated>
  </row>
  <row>
    <udiDi>00840140710304</udiDi>
    <basicUdiDi>B-00840140710304</basicUdiDi>
    <tradeName>Myogenin</tradeName>
    <deviceName>Myogenin</deviceName>
    <manufacturerName>Zeta Corporation</manufacturerName>
    <manufacturerSrn>US-MF-000008650</manufacturerSrn>
    <authorisedRepresentativeName>Emergo Europe B.V.</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000000116</authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>IVDD</legislation>
    <emdnCode>W01030709</emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Z2462ML</reference>
    <placedOnMarketCountry>Denmark</placedOnMarketCountry>
    <lastUpdated>2026-08-01T08:38:27.231Z</lastUpdated>
  </row>
</eudamedExport>